Irino S, Fujita J, Yamaji Y, Futami H, Hashimoto Y, Bungo M, Iuchi Y, Kamei M, Nakamura H, Hata Y
1st Dept. of Internal Medicine, Kagawa Medical School.
Gan To Kagaku Ryoho. 1989 Jun;16(6):2263-7.
Twenty-three patients with small cell lung cancer (11 with limited disease and 12 with extensive disease) who had not received previous chemotherapy were treated with a combination of adriamycin (30 mg/m2, i.v., on day 1), cisplatin (80 mg/m2, i.v., on day 1) and etoposide (70 mg/m2, i.v., on day 1-5). This chemotherapy regimen was repeated at 3- or 4-week intervals for 3 to 5 treatment cycles. Among 22 evaluable patients, 5 showed complete response and 17 had a partial response (response rate 100%). The median response duration of 12 extensive disease patients was 21 months. There were 5 survivors for more than 2 years. Toxicity included moderate to severe hematologic toxicity, alopecia, nausea and vomiting. This combination chemotherapy appears to be optimal for the treatment of small cell lung cancer.
23例未曾接受过化疗的小细胞肺癌患者（11例为局限期，12例为广泛期）接受了阿霉素（30mg/m²，静脉注射，第1天）、顺铂（80mg/m²，静脉注射，第1天）和依托泊苷（70mg/m²，静脉注射，第1 - 5天）联合治疗。该化疗方案每3或4周重复一次，共进行3至5个治疗周期。在22例可评估的患者中，5例完全缓解，17例部分缓解（缓解率100%）。12例广泛期疾病患者的中位缓解持续时间为21个月。有5例存活超过2年。毒性包括中度至重度血液学毒性、脱发、恶心和呕吐。这种联合化疗似乎是治疗小细胞肺癌的最佳方案。
